- Home
- XFOR vs CHRS Comparison
XFOR vs CHRS Comparison
Compare XFOR & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- CHRS
- Stock Information
- Founded
- XFOR 2014
- CHRS 2010
- Country
- XFOR United States
- CHRS United States
- Employees
- XFOR N/A
- CHRS N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XFOR Health Care
- CHRS Health Care
- Exchange
- XFOR Nasdaq
- CHRS Nasdaq
- Market Cap
- XFOR 118.4M
- CHRS 112.5M
- IPO Year
- XFOR N/A
- CHRS 2014
- Fundamental
- Price
- XFOR $3.40
- CHRS $0.78
- Analyst Decision
- XFOR Strong Buy
- CHRS Buy
- Analyst Count
- XFOR 3
- CHRS 3
- Target Price
- XFOR $72.33
- CHRS $4.68
- AVG Volume (30 Days)
- XFOR 180.2K
- CHRS 1.5M
- Earning Date
- XFOR 05-01-2025
- CHRS 05-12-2025
- Dividend Yield
- XFOR N/A
- CHRS N/A
- EPS Growth
- XFOR N/A
- CHRS N/A
- EPS
- XFOR 2.16
- CHRS N/A
- Revenue
- XFOR $31,364,000.00
- CHRS $272,251,000.00
- Revenue This Year
- XFOR $915.88
- CHRS N/A
- Revenue Next Year
- XFOR N/A
- CHRS $19.78
- P/E Ratio
- XFOR $1.57
- CHRS $1.83
- Revenue Growth
- XFOR N/A
- CHRS 19.87
- 52 Week Low
- XFOR $2.67
- CHRS $0.66
- 52 Week High
- XFOR $33.90
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- XFOR 39.83
- CHRS 40.90
- Support Level
- XFOR $2.67
- CHRS $0.74
- Resistance Level
- XFOR $3.56
- CHRS $0.82
- Average True Range (ATR)
- XFOR 0.28
- CHRS 0.07
- MACD
- XFOR 0.21
- CHRS -0.00
- Stochastic Oscillator
- XFOR 82.02
- CHRS 19.71
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.